ARDX Logo

Ardelyx, Inc. (ARDX) 

NASDAQ
Market Cap
$1.22B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
108 of 774
Rank in Industry
75 of 432

Largest Insider Buys in Sector

ARDX Stock Price History Chart

ARDX Stock Performance

About Ardelyx, Inc.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing …

Insider Activity of Ardelyx, Inc.

Over the last 12 months, insiders at Ardelyx, Inc. have bought $996,598 and sold $13.3M worth of Ardelyx, Inc. stock.

On average, over the past 5 years, insiders at Ardelyx, Inc. have bought $1M and sold $5.27M worth of stock each year.

Highest buying activity among insiders over the last 12 months: MOTT DAVID M (director) — $9.97M.

The last purchase of 215,868 shares for transaction amount of $996,598 was made by MOTT DAVID M (director) on 2024‑11‑13.

List of Insider Buy and Sell Transactions, Ardelyx, Inc.

2024-11-13Purchasedirector
215,868
0.0924%
$4.62$996,598+9.89%
2024-11-11SalePresident & CEO
2,743
0.0012%
$4.90$13,441-2.76%
2024-11-06SaleChief Development Officer
27,171
0.0109%
$6.10$165,743-24.19%
2024-11-04SaleChief Development Officer
27,172
0.0115%
$5.95$161,673-16.04%
2024-10-28SalePresident & CEO
25,000
0.0109%
$5.91$147,740-1.00%
2024-10-11SalePresident & CEO
7,500
0.003%
$6.01$45,075-2.81%
2024-09-27SaleChief Development Officer
49,564
0.0229%
$6.92$342,983-10.38%
2024-09-26SalePresident & CEO
3,000
0.0013%
$6.07$18,210+4.78%
2024-09-13SaleChief Development Officer
5,312
0.0022%
$6.26$33,254-5.23%
2024-09-11SalePresident & CEO
35,000
0.0147%
$5.61$196,3990.00%
2024-08-27SalePresident & CEO
7,500
0.0032%
$6.22$46,635-4.02%
2024-08-20SalePresident & CEO
32,225
0.0131%
$5.86$188,848-1.96%
2024-08-20SaleSee Remarks
4,969
0.002%
$5.86$29,120-1.96%
2024-08-20SaleChief Medical Officer
7,412
0.003%
$5.86$43,437-1.96%
2024-08-20SaleChief Financial Officer
5,289
0.0022%
$5.86$30,995-1.96%
2024-08-20SaleSee Remarks
7,089
0.0029%
$5.86$41,544-1.96%
2024-08-20SaleChief Development Officer
20,507
0.0085%
$6.00$123,042-1.96%
2024-08-20SaleChief Development Officer
27,726
0.0115%
$5.96$165,348-1.96%
2024-08-20SaleChief Development Officer
7,219
0.0029%
$5.86$42,306-1.96%
2024-08-20SaleSee Remarks
3,567
0.0015%
$5.86$20,904-1.96%

Insider Historical Profitability

37.65%
MOTT DAVID Mdirector
1425465
0.6018%
$5.1590+20.54%
RAAB MICHAELPresident & CEO
1207365
0.5098%
$5.15149+247.57%
Williams Laura AChief Medical Officer
314740
0.1329%
$5.15113+247.57%
Renz Justin AChief Financial Officer
295257
0.1247%
$5.15118+247.57%
GRAMMER ELIZABETH ASee Remarks
192380
0.0812%
$5.15239+116.79%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Janus Henderson$160.86M9.4222.05M-10.59%-$19.05M0.08
BlackRock$124.8M7.3117.1M+1.91%+$2.34M<0.01
State Street$102.85M6.0214.09M-17.62%-$22M<0.01
The Vanguard Group$97.76M5.7213.39M+2.81%+$2.67M<0.01
Eventide Asset Management$49.73M2.916.81M+0.11%+$54,560.200.8
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.